The present invention relates to a novel oral pharmaceutical composition in the form of a stable flocculated suspension in water, said composition comprising micronized megestrol acetate at a concentration of 10 to 200 mg per ml, polysorbate at a concentration of 0.01 % to 12.6 % weight by volume, or polyethylene glycol at a concentration of about 0.01 % to 5.0 % weight by volume, polyoxyl 35 castor oil at a concentration of 0.05 % to 51.5 % weight by volume and/or polyoxyl 40 hydrogenated castor oil at a concentration of 0.05 % to 45 % weight by volume in a stable flocculated suspension in water. The composition also may include preservatives, sweeteners, pH adjusting agents and flavoring agents.本發明關於一種新穎口服藥學組成物,其為在水中之安定絮狀懸浮液劑型,該組成物包含每毫升約10至200毫克之微粉化醋酸美皆斯妥、濃度約0.01至12.6%(重量/體積)之聚山梨醇酯80,或濃度約0.01至5.0%(重量/體積)之聚乙二醇400、濃度約0.05至51.5%(重量/體積)之聚氧乙烯醚(35)蓖麻油,及/或濃度約0.05至45%(重量/體積)之聚氧乙烯醚(40)氫化蓖麻油。該組成物亦可包含防腐劑、甜味劑、pH調整劑及香味劑等。
